CLINICAL AND ECONOMIC ANALYSIS OF USING OF LONG ACTION ERYTHROPOES STIMULATED AGENTS FOR THE TREATMENT OF ANEMIA CKD V HD PATIENTS

  • M. Kolesnyk SI «Institute of Nephrology NAMS of Ukraine»
  • N. Bezdetko National University of Pharmacy Kharkiv
  • V. Novakivskyy SI «Institute of Nephrology NAMS of Ukraine»
Keywords: pharmacoeconomic, anemia, ESA (erythropoes stimulated agents), hemodialysis, hemodiafiltration, pegilated erythropoietin - p, darbopoietin - a, Darbepoetin, long - сcontinuous erythropoietin receptor activator (CERA), chronic kidney diseases (CKD).

Abstract

The article describes the ways to cost optimization of anemia treatment CKD - HD patients.

Aims. dinical and economic analysis treatment of Anemia CKD VHD PTS with using long action Erythropoiesis Stimulating Agents (ESA).

Methods. We calculated the true cost of anemia therapy with darbepoetin alfa compared to the methoxypolyethyleneglycol - epoetin beta.

Results. It was established that average cost of therapy with methoxypolyethyleneglycol - epoetin beta was lower than darbepoetin alfa provided declared, wholesale or retail prices of25 - 60%.

Conclusions. The methoxypolyethyleneglycol - epoetin beta haspharmacoeconomics advantages in comparison with the darbepoetin alfa in treatment of anemia CKD V HD patients.

Downloads

Download data is not yet available.

References

Аптека on line. – [Электронный ресурс]. – Режим доступа к сайту http://www.pharmbase.com.ua

Державний формуляр лікарських засобів – [Электронный ресурс]. – Режим доступа к сайту http:// www.dec.gov.ua

Дудар І. О., Гончар Ю.І. Якість життя пацієнтів із хронічними хворобами нирок, яких лікують з використанням методів ниркової замісної терапії // Therapia. - 2007. - № 11. - С. 75 - 80.

Колесник М.О., Суржко Л.М. Використання дарбепоетину альфа для лікування анемії у хворих нефрологічного профілю. //Український журнал нефрології та діалізу. – 2011. – № 2. – С. 71 - 79.

Колесник Н.А. Специализированная медицинская помощь больным нефрологического профиля в мире и в Украине: оценка ситуации и прогнозы. // Therapia. - 2011. - № 1. - С. 6 - 8.

Куликов А.Ю., Аринина Е.Е. Анализ минимизации затрат на терапию нефрогенной анемии эритропоэзстимулирующими средствами у пациентов с хронической болезнью почек, не получающих диализ. // Фармакоэкономика. - 2009. - Т. 2. - №4. - С.34 - 37.

Фармакоекономіка. /Л.В.Яковлєва, Н.В. Бездітко, О.О. Герасимова та їнш. - Вінниця: Нова книга, 2009. - 208 с.

Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Национальные рекомендации. // Нефрология. - 2012. - №1. - С. 89 - 115.

Alsalimy N, Awaisu A. Methoxy polyethylene glycolepoetin beta versus darbepoetin alfa for anemia in nondialysis - dependent CKD: a systematic review. //Int. J. Clin. Pharm. - 2014. - Vol. 36. - №6. - P. 1115 - 1125.

Anaemia Management in Chronic Kidney Disease: Partial Update 2015 NICE Guideline, No. 8. - National Clinical Guideline Centre (UK), London: Royal College of Physicians (UK). - 2015. 276 p.

Anemia of renal disease: what it is, what to do and what’s new. /S. Chalhoub, C. Langston, A. Eatroff //J. Feline. Med. Surg. - 2011. - Vol. 13. - №9. - P.629 - 640.

Comparative mortality risk of anemia management practices in incident hemodialysis patients /M.A. Brookhart, S.Schneeweiss, J.Avon et al. //Jama. - 2010. - Vol. 303. - №9. - P.857 - 864.

Comparison between shortand long - acting erythropoiesis - stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome. /B.Bernieh, S.Abouchacra, Y.Boobes et al. //Int. Urol. Nephrol. - 2014. - Vol. 46. - №2. - P. 453 - 459.

Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non - dialysis chronic kidney disease patients. /R.Minutolo, P.Zamboli, P. Chiodini et al. //Blood Purif. - 2010. - Vol.30. - P.186 - 194.

Cost - Utility Analysis of Erythropoietin for Anemia Treatment in Thai End - Stage Renal Disease Patients with Hemodialysis /T. Thaweethamcharoen, R. Sakulbumrungsil, C. Nopmaneejumruslers et al. //Value in Health regional issues. - 2014. № 3. - P. 44 - 49.

Curran M.P., McCormack P.L. Methoxy polyethylene glycol - epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. //Drugs - 2008. - Vol. 68. - №8. - P.1139 - 1156.

Darbepoetin for the anaemia of chronic kidney disease. /S.Palmer, V.Saglimbene, C.Craig et al. //Cochrane Database Syst. Rev. - 2014. - Mar 31; 3. - [Электронный ресурс]. - Режим доступа к сайту http://www.thecochranelibrary.com

Dose of erythropoiesis - stimulating agents and adverse outcomes in CKD: a metaregression analysis. /I.Koulouridis, M. Alfayez, T.Trikalinos et al. //Am. J. Kidney Dis. - 2013. - Vol. 61. - №1. - P. 44 - 56.

Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. /J.Hymes, T.Bickimer, J.Jacksonet al. //Curr. Med. Res. Opin. - 2007. - Vol. 23. - №8. - P.1931 - 1937.

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. /M.Davis - Ajami, J.Wu, K.Downton et al.//Biologics : Targets & Therapy. - 2014 - №8. - P. 155 - 167.

Erythropoiesis - stimulating agents (ESA) for preventing the progression of chronic kidney disease: a meta - analysis of 19 studies. /A. Covic, I.Nistor, M.Donciu et al. // Am. J. Nephrol. - 2014. - Vol. 40. - №3. - P.263 - 279.

Erythropoiesis - stimulating agents for anaemia in adults with chronic kidney disease: a network meta - analysis. /S.Palmer, V.Saglimbene, D.Mavridis et al. // Cochrane Database Syst. Rev. - 2014. - Dec 8; 12. - [Электронный ресурс]. - Режим доступа к сайту http://www.thecochranelibrary.com

Erythropoiesis - stimulating agents in anaemia due to chronic kidney disease: a cost - minimization analysis. /V Escudero - Vilaplana, C.Mart nez - Nieto, M. L pezG mez et al. //Int. J. Clin. Pharm. - 2013. - Vol. 35. - №3. - P.463 - 468.

Frequency of administration of erythropoiesis - stimulating agents for the anaemia of end - stage kidney disease in dialysis patients. /D.Hahn, J. Cody, E. Hodson //Cochrane Database Syst. Rev. - 2014. - May 28; 5. - [Электронный ресурс]. - Режим доступа к сайту http://www.thecochranelibrary.com

Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. /G.F. Strippoli, C. Manno, F.P.Schena et al. //Cochrane Database Syst Rev. - 2006. - Is. 4. - 77 p.

Horl W.H. Differentiating factors between erythropoiesis - stimulating agents: an update to selection for anaemia of chronic kidney disease. //Drugs. - 2013. - Vol. 73. - №2. - P.117 - 130.

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. /B.Canaud, G.Mingardi, J.Braun et al. //Nephrol. Dial. Transplant. - 2008. - Vol. 23. - №11. - P. 36543661.

Intravenous methoxy polyethylene glycol - epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non - inferiority trial (MAXIMA). /N.Levin, S.Fishbane. F.Cafiedo et al. //Lancet. - 2007. - Vol. 370. - P.1415 - 1421.

Kruep E, Basskin L. Cost - minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. // Am. J. Health - Syst. Pharm. - 2005. - Vol 62 - P. 25962603.

Longer - term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi - experimental Cohort Study. /W.C. Winkelmayer, T.I. Chang, A. Mitani et al //Am. J. Kidney. Dis. - 2015. - Vol. 66. - №1. - P. 106 - 113.

Low hemoglobin levels and hypo - responsiveness to erythropoiesis - stimulating agent associated with poor survival in incident Japanese hemodialysis patients. / T. Akizawa, A.Saito, F.Gejyo et al //Ther. Apher. Dial. - 2014. - Vol.18. - № 5. - P. 404 - 413.

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol - epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. /F.Carrera, C.Lok, A.de Francisco et al. //Nephrol. Dial. Transplant. - 2010. - Vol. 25. - P. 4009 - 4017.

Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. /F. Locatelli, A.de Francisco, G. Deray et al. //Nephron Clin. Pract. - 2014. - Vol.128. - №3 - 4. - P.323 - 332.

Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. /Y.Vanrenterghem, P.Barany, J.F. Mann et al. //Kidney Int. - 2002. - Vol. 62. - P.2167 - 2175

Randomized, controlledtrial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. /A.Nissenson, S.Swan, J.Lindberg et al. //Am. J. Kidney Dis. - 2002. - Vol. 40. - P. 110 - 118.

Rascati K.L. Essentials of Pharmacoeconomics. - Philadelphia, PA: Lippincott Williams & Wilkins, 2013. - 250 p.

Schmid H. Cost - effectiveness of continuous erythropoietin receptor activator in anemia. //Clinicoecon. Outcomes Res. - 2014. - Vol. 6. - P.319 - 330.

Switch of methoxy - polyethylene - glycol - epoetin beta to darbepoetin alfa in 263 dialysis patients. /J. Rieger, T.Krummel, P.Petitjean et al. // Ann. Pharm. Fr. - 2015. - Vol. 73. - Is. 5.

Topf J.M. CERA: third - generation erythropoiesis - stimulating agent. //Expert. Opin. Pharmacother. - 2008. - №9. - P.839 - 849.

Wilhelm - Leen E.R., Winkelmayer W.C. Mortality Risk of Darbepoetin Alfa Versus Epoetin Alfa in Patients With CKD: Systematic Review and Meta - analysis. //Am. J. Kidney. Dis. - 2015 - Vol. 66. - №1. - P. 69 - 74.


Abstract views: 231
PDF Downloads: 120
Published
2015-08-25
How to Cite
Kolesnyk, M., Bezdetko, N., & Novakivskyy, V. (2015). CLINICAL AND ECONOMIC ANALYSIS OF USING OF LONG ACTION ERYTHROPOES STIMULATED AGENTS FOR THE TREATMENT OF ANEMIA CKD V HD PATIENTS. Ukrainian Journal of Nephrology and Dialysis, (3(47), 65-70. https://doi.org/10.31450/ukrjnd.3(47).2015.11

Most read articles by the same author(s)